Malta - English - Medicines Authority

fresenius kabi oncology plc - carboplatin - concentrate for solution for infusion - carboplatin 10 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced ovarian carcinoma of epithelial origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced ovarian carcinoma of epithelial origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced ovarian carcinoma of epithelial origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections - indications for uk market - treatment of some types of lung cancer and ovarian cancer. indications for france market - it is recommended for the treatment of certain diseases of the ovaries, bronchi and aerodigestive pathways. indications for greece and cyprus market - carboplatin is a second-generation cisplatin derivative which has shown to possess antitumor activity against a number of malignancies. the drug is indicated for the treatment of the following solid tumours: ?advanced ovarian carcinoma of epithelial origin. ?small cell lung cancer. ? non-small cell lung cancer.? epidermoid head and neck cancer. ? transitional cell cancer of the bladder (in combination with other cytostatic agents). ? cervical carcinoma in case of failure or unacceptable toxicity of cisplatin treatment or when the doctor considers that it cannot be tolerated.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الغروب - sun set drug store - carboplatin 10 mg/ml - 10 mg/ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الغروب - sun set drug store - carboplatin 10 mg/ml - 10 mg/ml

United States - English - NLM (National Library of Medicine)

accord healthcare, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative treatment of patients with ovar

United States - English - NLM (National Library of Medicine)

sandoz inc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with c